- Home
- GENC vs ZNTL Comparison
GENC vs ZNTL Comparison
Compare GENC & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENC | ZNTL |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 118.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GENC | ZNTL |
|---|---|---|
| Price | $13.15 | $1.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.87 |
| AVG Volume (30 Days) | 27.7K | ★ 755.0K |
| Earning Date | 12-09-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.92 | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $115,437,000.00 | $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.91 | ★ N/A |
| Revenue Growth | ★ 2.01 | N/A |
| 52 Week Low | $10.80 | $1.01 |
| 52 Week High | $19.91 | $3.33 |
Technical Indicators
Market Signals| Indicator | GENC | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.59 | 50.81 |
| Support Level | $12.86 | $1.34 |
| Resistance Level | $13.68 | $1.45 |
| Average True Range (ATR) | 0.59 | 0.07 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 22.44 | 58.82 |
Price Performance
Historical ComparisonAbout GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.